We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Eversense 365 offers up to a year of glucose monitoring, while iLet automates insulin dosing.
BBNX plans to integrate Eversense 365 with its Mint patch pump, further expanding insulin delivery choices.
Beta Bionics, Inc. (BBNX - Free Report) and Senseonics Holdings, Inc. (SENS - Free Report) have commercially launched the integration of Beta Bionics' iLet Bionic Pancreas with Senseonics' Eversense 365 continuous glucose monitoring (CGM) system. The launch marks an important milestone in the companies' previously announced partnership and expands the range of diabetes management solutions available to patients.
The integration is expected to strengthen BBNX's position in the automated insulin delivery market by expanding the compatibility of its iLet system with advanced CGM technology. The partnership could enhance the appeal of the iLet platform, support patient adoption and create additional growth opportunities for BBNX. Over the longer term, expanding its technology ecosystem and offering patients greater choice in CGM integration could help the company strengthen its competitive position in diabetes care.
BBNX Stock Trend
Year to date, the stock plunged 50.1%, underperforming the industry’s 2.4% growth and the S&P 500’s 7.2% gain.
The integration is likely to strengthen BBNX's competitive positioning in the automated insulin delivery market by expanding the CGM options compatible with its iLet Bionic Pancreas. The device already integrates with Dexcom's G6 and G7 CGM systems and Abbott's FreeStyle Libre 3 Plus sensor.
The addition of SENS' Eversense 365 further broadens patient choice and enhances the flexibility of the iLet platform. This expanded compatibility could help BBNX attract a wider patient base, support adoption of its insulin delivery system and strengthen its presence in the growing diabetes technology market. For SENS, the partnership provides an additional distribution and market access opportunity for Eversense 365, potentially driving sensor adoption and expanding its presence in the automated insulin delivery market.
Over the longer term, the integration could create a mutually beneficial growth opportunity by combining BBNX's insulin delivery technology with SENS' long-term glucose monitoring platform, while offering patients greater flexibility in diabetes management.
BBNX currently has a market capitalization of $892.7 million.
Image Source: Zacks Investment Research
More on the News
Eversense 365 offers continuous glucose monitoring for up to 365 days with a single implanted sensor and provides accurate glucose readings, including at low glucose levels. Its long-term sensing capability reduces the frequency of sensor replacements and disruptive false alerts compared with traditional CGM systems, potentially lowering the daily device management burden for patients.
Meanwhile, BBNX's iLet Bionic Pancreas uses CGM data and a proprietary algorithm to autonomously determine and deliver insulin doses based on individual insulin requirements. The system does not require carbohydrate counting or manual correction boluses, although users must remain aware of their carbohydrate intake. It learns and adapts to individual insulin needs, helping simplify diabetes management.
The commercial launch follows the partnership announced by BBNX and SENS in September 2026, with both companies meeting their previously communicated fourth-quarter 2026 launch timeline. The companies have also committed to integrating Eversense 365 with Mint, BBNX's tubeless insulin patch pump, in the future. This planned integration is expected to further expand insulin delivery choices for Eversense 365 users and strengthen the companies' collaboration in the automated insulin delivery market.
Industry Prospects Favoring the Market
Per a report by Data Bridge Market Research, the global automated insulin delivery devices market size was valued at $3.29 billion in 2024 and is projected to reach $7.83 billion by 2032, at a CAGR of 11.43%.
The global automated insulin delivery devices market is experiencing significant growth, driven by the rising prevalence of diabetes and advancements in technology.
Other News
In September, BBNX secured FDA clearance for its Mint patch pump, marking a key milestone in expanding its automated insulin delivery portfolio. The company also unveiled its next-generation 3D Intelligence insulin dosing algorithm, which is currently under FDA review. The company outlined commercialization timelines for both innovations.
BBNX’s Zacks Rank & Key Picks
Currently, BBNX carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Glaukos (GKOS - Free Report) and Intuitive Surgical (ISRG - Free Report) .
Glaukos, currently flaunting a Zacks Rank #1 (Strong Buy), reported third-quarter 2026 adjusted earnings per share (EPS) of 47 cents, which surpassed the Zacks Consensus Estimate by 491.7%. Revenues of $211 million beat the Zacks Consensus Estimate by 25%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GKOS has an estimated earnings growth rate of 155.6% for 2026. The company’s earnings beat estimates in three of the trailing four quarters and missed once, the average surprise being 138.6%.
Intuitive Surgical, currently carrying a Zacks Rank #2 (Buy), reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 15.5%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.
Image: Bigstock
BBNX & SENS Launch Eversense 365 Integration With iLet Bionic Pancreas
Key Takeaways
Beta Bionics, Inc. (BBNX - Free Report) and Senseonics Holdings, Inc. (SENS - Free Report) have commercially launched the integration of Beta Bionics' iLet Bionic Pancreas with Senseonics' Eversense 365 continuous glucose monitoring (CGM) system. The launch marks an important milestone in the companies' previously announced partnership and expands the range of diabetes management solutions available to patients.
The integration is expected to strengthen BBNX's position in the automated insulin delivery market by expanding the compatibility of its iLet system with advanced CGM technology. The partnership could enhance the appeal of the iLet platform, support patient adoption and create additional growth opportunities for BBNX. Over the longer term, expanding its technology ecosystem and offering patients greater choice in CGM integration could help the company strengthen its competitive position in diabetes care.
BBNX Stock Trend
Year to date, the stock plunged 50.1%, underperforming the industry’s 2.4% growth and the S&P 500’s 7.2% gain.
The integration is likely to strengthen BBNX's competitive positioning in the automated insulin delivery market by expanding the CGM options compatible with its iLet Bionic Pancreas. The device already integrates with Dexcom's G6 and G7 CGM systems and Abbott's FreeStyle Libre 3 Plus sensor.
The addition of SENS' Eversense 365 further broadens patient choice and enhances the flexibility of the iLet platform. This expanded compatibility could help BBNX attract a wider patient base, support adoption of its insulin delivery system and strengthen its presence in the growing diabetes technology market. For SENS, the partnership provides an additional distribution and market access opportunity for Eversense 365, potentially driving sensor adoption and expanding its presence in the automated insulin delivery market.
Over the longer term, the integration could create a mutually beneficial growth opportunity by combining BBNX's insulin delivery technology with SENS' long-term glucose monitoring platform, while offering patients greater flexibility in diabetes management.
BBNX currently has a market capitalization of $892.7 million.
Image Source: Zacks Investment Research
More on the News
Eversense 365 offers continuous glucose monitoring for up to 365 days with a single implanted sensor and provides accurate glucose readings, including at low glucose levels. Its long-term sensing capability reduces the frequency of sensor replacements and disruptive false alerts compared with traditional CGM systems, potentially lowering the daily device management burden for patients.
Meanwhile, BBNX's iLet Bionic Pancreas uses CGM data and a proprietary algorithm to autonomously determine and deliver insulin doses based on individual insulin requirements. The system does not require carbohydrate counting or manual correction boluses, although users must remain aware of their carbohydrate intake. It learns and adapts to individual insulin needs, helping simplify diabetes management.
The commercial launch follows the partnership announced by BBNX and SENS in September 2026, with both companies meeting their previously communicated fourth-quarter 2026 launch timeline. The companies have also committed to integrating Eversense 365 with Mint, BBNX's tubeless insulin patch pump, in the future. This planned integration is expected to further expand insulin delivery choices for Eversense 365 users and strengthen the companies' collaboration in the automated insulin delivery market.
Industry Prospects Favoring the Market
Per a report by Data Bridge Market Research, the global automated insulin delivery devices market size was valued at $3.29 billion in 2024 and is projected to reach $7.83 billion by 2032, at a CAGR of 11.43%.
The global automated insulin delivery devices market is experiencing significant growth, driven by the rising prevalence of diabetes and advancements in technology.
Other News
In September, BBNX secured FDA clearance for its Mint patch pump, marking a key milestone in expanding its automated insulin delivery portfolio. The company also unveiled its next-generation 3D Intelligence insulin dosing algorithm, which is currently under FDA review. The company outlined commercialization timelines for both innovations.
BBNX’s Zacks Rank & Key Picks
Currently, BBNX carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Glaukos (GKOS - Free Report) and Intuitive Surgical (ISRG - Free Report) .
Glaukos, currently flaunting a Zacks Rank #1 (Strong Buy), reported third-quarter 2026 adjusted earnings per share (EPS) of 47 cents, which surpassed the Zacks Consensus Estimate by 491.7%. Revenues of $211 million beat the Zacks Consensus Estimate by 25%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GKOS has an estimated earnings growth rate of 155.6% for 2026. The company’s earnings beat estimates in three of the trailing four quarters and missed once, the average surprise being 138.6%.
Intuitive Surgical, currently carrying a Zacks Rank #2 (Buy), reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 15.5%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.